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Cyclooxygenase 2 Expression in Rectal Cancer Is of Prognostic
Significance in Patients Receiving Preoperative Radiotherapy
Pieter de Heer,1Marleen J.E.M. Gosens,4,7 Elza C. de Bruin,2 N. Geeske Dekker-Ensink,1
Hein Putter,3 Corrie A.M.Marijnen,6 AdriaanJ.C. van den Brule,5 J. HanJ.M. van Krieken,7
Harm J.T. Rutten,4 PeterJ.K. Kuppen,1 and CornelisJ.H. van deVelde,1
for the Dutch Colorectal Cancer Group
Abstract Purpose:To determine the effect of cyclooxygenase (COX)-2 expression on clinical behavior in
irradiated and nonirradiated rectal carcinomas.
Experimental Design:Tumor samples were collected from1,231patients of the DutchTME trial,
in which rectal cancer patients were treated with standardized surgery and randomized for
preoperative short-term (5  5 Gy) radiotherapy or no preoperative radiotherapy. Tissue micro-
arrays were constructed from primary tumor material, and COX-2 expression was assessed by
immunohistochemistry.Tumor cell apoptosis was determined by M30 immunostaining.
Results: A high level of COX-2 expression after radiotherapy was associated with low levels of
tumor cell apoptosis (P =0.001). COX-2 expressionhadno significant effect onpatient survival or
tumor recurrence in nonirradiated tumors. However, in patients receiving preoperative radiothera-
py, high level of COX-2 expression was associated with higher incidence of distant recurrences
[P = 0.003; hazard ratio (HR), 1.7; 95% confidence interval (95% CI), 1.2-2.5] and shorter
disease-free survival (P = 0.002; HR, 1.8; 95% CI, 1.2-2.5) and overall survival (P = 0.009; HR,
1.5; 95% CI, 1.1-2.0), independent of patient age, tumor stage, tumor location, or the presence of
tumor cells in the circumferential resectionmargin.
Conclusions: A high level of COX-2 expression after preoperative radiotherapy in resection
specimens is associated with apoptosis resistance, high distant recurrence rates, and a poor
prognosis in rectal cancer.
In recent years, the role of a key enzyme in prostaglandin
synthesis, cyclooxygenase (COX)-2, has been appreciated in
cancer development and progression. COX-2 is responsible for
the conversion of arachidonic acid to prostaglandins and other
eicosanoids. In addition to its well-known role in inflammatory
reactions, COX-2 plays a role in tumor progression, angiogen-
esis, metastatis, and abrogation of the antitumor immune
response (1–4). COX-2 prevents apoptosis by generation of
antiapoptotic PGE2 (5) and PGI2 (6) and by removal of the
proapoptotic substrate arachidonic acid (7). PGE2 induces
transformations that result in increased Bcl-2 expression and
prolong the cell cycle G1 phase with increased cyclin D1
expression (8). Numerous epidemiologic studies have indicated
that the use of nonsteroidal antiinflammatory drugs, and
COX-2 inhibitors is associated with a significant decreased
incidence and mortality rate in colorectal cancer (9–12). In
addition, selective COX-2 inhibitors have been shown to
decrease COX-2 expression and COX-2 activity in gastrointes-
tinal malignancies (13). The clinical effect of COX-2 expression
has been evaluated in a large number of studies in colorectal
cancer and results have not been consistent (9, 14, 15).
Considering the distinct differences in tumor biology (16),
treatment, recurrence rates, and metastatic behavior, it is
regrettable that most studies make no distinction between
rectal and colon cancer.
The purpose of the current study was to obtain a conclusive
answer of the clinical relevance and prognostic value of
immunohistochemically determined COX-2 expression in
rectal cancer and to investigate the effects of radiation therapy
on COX-2 expression and subsequent biological and clinical
behavior. The investigated patients were included in the Dutch
TME trial, a prospective multicenter trial, and were randomized
between standardized preoperative radiotherapy treatment
followed by TME surgery or TME surgery alone (17).
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Materials andMethods
Study population. Patients were obtained from the Dutch TME trial, a
large multicenter trial in which 1,861 patients were included from
January 1996 until December 1999. Patients with a resectable
carcinoma of the rectum were included in this international multicenter
clinical trial and were subsequently randomized for radiotherapy
(5  5 Gy) followed by TME surgery or for TME surgery alone without
preoperative radiotherapy (17). Radiotherapeutic, surgical, and patho-
logic procedures were standardized and quality controlled (17, 18, 19).
Patients who complied with the eligibility criteria of the TME trial (17)
with sufficient paraffin-embedded tumor material were selected for this
study. Archival tumor material was collected from the 1,530 Dutch
patients who were included in the trial. Tumor material was available
from 1,231 patients. For the evaluation of COX-2 expression, patients
were only included if at least two of the three included punches on the
tissue microarray could be evaluated, leaving 1,038 eligible stages I to
III rectal cancer patients for analyses of clinical effect of COX-2
expression.
Tissue microarray preparation. Tissue microarrays from formalin-
fixed, paraffin-embedded tumors included in the Dutch TME trial were
constructed with a custom-built precision tissue arrayer (Beecher Instru-
ments) using a 2-mm-diameter punch as described previously (20).
Immunohistochemistry. For the quantification of COX-2 expression,
4-Am sections of the tissue microarrays were stained with COX-2–
specific mouse anti-human monoclonal antibodies (clone CX229,
Cayman Chemical Co.). The immunohistochemical procedures were
described in detail elsewhere (21). Antigen retrieval was done by
boiling the sections in 10 mmol/L citrate buffer (pH 6.0) for 10 min.
Sections were incubated overnight at room temperature with antibodies
against human COX-2 (1:100). Specificity of the antibodies was
confirmed in this study by staining randomly selected rectal cancer
specimens with and without preabsorption of the primary antibody
with human COX-2 antibody–blocking peptides (10 AL/mL; Cayman
Chemical) for 1 h at room temperature before the staining procedure.
All tumor specimens were stained simultaneously to avoid interassay
variation. COX-2 immunostaining was assessed by two independent
observers (P.H. and M.J.E.M.G.) in a blinded manner.
For high-throughput analysis of the tissue microarrays, the scoring
criteria proposed by Buskes et al. (21) was used: score 0, no staining;
score 1, weak diffuse cytoplasmatic staining (may contain stronger
intensity in <10% of the cancer cells); score 2, moderate to strong
granular cytoplasmatic staining in 10–90% of the tumor cells; and
score 3, >90% of the tumor cells stained with strong intensity. The three
stained tissue microarray punches taken from each tumor were scored
independently. The median score of the punches was used for analysis.
In case of disagreement, a consensus score was obtained. In the present
study, COX-2 scores 0, 1, and 2 were defined as COX-2 low, and a score
of 3 was defined as COX-2 high.
Apoptosis levels had previously been characterized in this series
of patients by immunohistochemical analysis of M30 expression (20).
Data on COX-2 expression and apoptosis was available in 1,024
patients.
Statistical analyses. All analyses were done with SPSS statistical
software (version 12.0 for Windows, SPSS Inc.). Paired samples t test,
Mann-Whitney U , Kruskall-Wallis, and Spearman’s q tests were used
to compare continuous variables. The m2 test was used to compare
categorical variables. Patient survival was estimated according to the
Kaplan-Meier method and compared using the log-rank test. The entry
date for the survival analyses was the time of surgery of the primary
tumor. Events for time to local recurrence, distant recurrence, disease-
free, and overall survival were defined as from the time of surgery to the
time of local disease relapse, time of distant disease relapse, time of
disease relapse or death, and time of death, respectively. COX regression
analyses were used to calculate hazard ratios (HR) with 95% confidence
intervals (95% CI). Variables with a P value of V0.10 in the univariate
analyses were subjected to a multivariate analysis. Interobserver
variability was calculated by j statistic as described by Landis and
Koch: j values of 0.2 to 0.4 indicate fair; 0.4 to 0.6, moderate; and
of > 0.6, excellent results (22).
Results
COX-2 protein expression in rectal cancer tissue microarrays.
The immunohistochemical COX-2 staining pattern exhibited a
brown diffuse granular cytoplasmatic staining (Fig. 1). No
staining of COX-2 was observed in five tumors (0.5%; Fig. 1A).
A weak diffuse, moderate, or strong staining was observed in
respectively 114 (11.0%), 602 (58.0%), and 317 (30.5%) of the
tumors (Fig. 1B-D).
The interobserver j-value score for evaluation of COX-2
expression was 0.62, indicating minimal interobserver varia-
tion. Ten randomly selected rectal cancer specimens were
stained with COX-2 antibodies with or without blocking
peptide. All tumor cell signals were blocked by this control
procedure in all specimens.
COX-2 expression and clinicopathologic variables. Clinical
data and conventional prognosis factors (tumor-node-metasta-
sis stage, age, histology, localization) of the patients in the
current study have been published previously (17, 20). COX-2
expression did not significantly differ between irradiated and
Fig. 1. Representative stainings of COX-2 expression in tissue microarray cores
from the1,231rectal cancer specimens evaluated in this study. A, COX-2^ negative
tumor (score 0). B, weak diffuse cytoplasmatic staining (score1). C, moderate to
strong granular cytoplasmatic staining (score 2). D, strong intensity of the staining
(score 3).
Table 1. Distribution of COX-2 expression in
irradiated and nonirradiated rectal cancer
specimens
COX-2 TME RT+ TME Total
0 3 (0.6%) 2 (0.4%) 5 (0.5%)
1 51 (9.7%) 63 (12.4%) 114 (11%)
2 300 (56.8%) 302 (59.2%) 602 (58%)
3 174 (33.0%) 143 (28.0%) 317 (30.5%)
Total 528 510 1038
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nonirradiated tumors (P = 0.27; Table 1) and were distributed
evenly in nonirradiated and irradiated patients with regard to
various clinical and pathologic variables, such as age, gender,
tumor size, depth of invasion, lymph node involvement,
tumor-node-metastasis stage, type of surgery, circumferential
margin and distance from anal verge. All P values were not
significant (data not shown). A poor grade of differentiation
was borderline significantly associated with high COX-2
expression levels in nonirradiated tumors (P = 0.06). High
levels of COX-2 expression were more often observed in
adenocarcinomas (compared with tumors of the mucinous
type) in irradiated and nonirradiated tumors (P = 0.05/0.04).
COX-2 expression in relation to radiotherapy and apoptosis.
COX-2 expression was not associated with apoptosis in
resection specimens of nonirradiated rectal cancer tumors
(P = 0.13) but was significantly associated with decreased
levels of apoptosis (20) in irradiated tumors (P = 0.001, Mann-
Whitney test). As can be seen in Fig. 2, the analysis remained
significant when COX-2 scores were dichotomized as scores
0 to 2 (COX-2 low) versus score 3 (COX-2 high; P = 0.001,
Mann-Whitney test).
The median time period from completion of radiotherapy
to surgery was 4 days (interquartile range, 3-6 days). No
significant differences were observed between the levels of
COX-2 expression with regard to the median time between
radiotherapy and surgery (P = 0.06, Kruskall-Wallis test).
COX-2 expression in relation to radiotherapy and tumor
prognosis. Subsequently, we analyzed the effect of COX-2 ex-
pression on tumor recurrence and patient survival. Figure 3A-C
shows the effect of COX-2 expression in nonirradiated tumors
on local recurrence rates, overall survival, and disease-free
survival.
COX-2 expression did not have an effect on local recurrence
(P = 0.44; Fig. 3A), distant recurrences (P = 0.77; Fig. 4), overall
survival (P = 0.61; Fig. 3B), or disease-free survival (P = 0.57;
Fig. 3C) in nonirradiated rectal cancer specimens. As can be
seen in Fig. 4, after radiotherapy, tumors with high levels
of COX-2 expression showed a significantly higher rate of
distant recurrences (P = 0.005), but this was not observed in
nonirradiated tumors. Figure 5A-C shows tumors with high
levels of COX-2 expression after radiotherapy to be associated
with poor disease-free survival (P = 0.004) and overall survival
(P = 0.006) but not with local recurrence rates (P = 0.92).
Univariate and multivariate analyses in irradiated patients.
Univariate COX regression analyses were done to identify
prognostic factors for overall survival in irradiated patients.
Advanced patient age (HR, 1.03, 95% CI, 1.01-1.05; P <
0.0001), advanced pathologic stage (HR, 1.75; 95% CI, 1.47-
2.03; P < 0.0001), tumor-positive circumferential resection
margins (HR, 2.46; 95% CI, 1.82-3.33; P < 0.0001), distal
location of the tumor (HR, 1.46; 95% CI, 1.01-2.06; P = 0.05)
and high COX-2 expression (HR, 1.48; 95% CI, 1.11-1.96;
Fig. 2. Dichotomized COX-2 expression is associated with decreased levels of
apoptosis in irradiated tumor specimenswithhigh levels of COX-2 expression. Black
columns, patients receiving preoperative radiotherapy followed byTME surgery.
Gray columns, patients receivingTME surgery alone.
Fig. 3. Kaplan-Meier survival estimates by dichotomized COX-2 tumor epithelial staining in nonirradiated rectal tumors for local recurrence (A), overall survival (B), and
disease-free survival (C). Gray lines, low levels of COX-2; black lines, high levels of COX-2 expression.
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P = 0.006) proved to be significant in the univariate analyses
and were subjected to COX multivariate analysis (Table 2).
Patient age above the median, advanced pathologic stage,
tumor-positive circumferential resection margins, and high
COX-2 expression (HR, 1.46; 95% CI, 1.10-1.94; P = 0.009)
retained their strength as independent prognostic factors for
overall survival (Table 2). In addition, COX-2 proved to be an
independent prognostic factor for high distant recurrence rates
(P = 0.003; HR, 1.7; 95% CI, 1.2-2.5) and disease-free survival
(P = 0.002; HR, 1.8; 95% CI, 1.2-2.5).
Discussion
The major observation in the current study is that increased
COX-2 expression in irradiated rectal cancer specimens is
associated with reduced levels of apoptosis and poor prognosis.
This indicates that COX-2 expression can be used to identify a
cohort of patients with a poor prognosis after radiotherapy.
In several forms of cancer, radiation exposure is associated
with an increase in eicosanoid production. Within hours after
radiation, increased levels of prostaglandin’s and thrombox-
anes are detectable in most tissues, and increased levels may
persist for several days or weeks (23, 24). In the current study,
high COX-2 expressions after radiotherapy were associated with
apoptosis resistance and can therefore lower levels of radio-
therapy-induced apoptosis.
Antiapoptotic proteins of the Bcl-2 family are able to
suppress radiation-induced cell death (25). COX-2 is known
to induce Bcl-2 expression (4) and is associated with apoptosis
resistance (8). De Bruin et al. (20) showed, by immunohisto-
chemical evaluation of M30, that intrinsic apoptosis is a
prognostic factor for local recurrence in rectal cancer. However
radiotherapy-induced apoptosis was not of prognostic value
(26). Because the current study found a prognostic effect of
COX-2 in irradiated patients only, whereas apoptotic rates were
only prognostic in nonirradiated cases, our findings cannot
provide a mechanistic explanation of our observations in
relation with tumor cell apoptosis.
A possible explanation for the clinical behavior of tumors
with high levels of COX-2 expression after radiotherapy lies in
the fact that COX-2 is an immediate early response gene (27).
The interval between the short-term radiotherapy and surgery
could be sufficient for a change in COX-2 activity and sub-
sequent prostaglandin production to influence the clinical
behavior of the tumor (23, 28). Elevated COX-2 expression has
shown to lead to alterations in the invasive and metastatic
potential of cancer cells (2). COX-2 expression and prostaglan-
din production induce cell-surface glysosyltransferases and type
1 sialyl Lewis antigens, leading to enhanced tumor cell
adhesion to endothelial cells (29, 30). And animal studies
reported that COX-2 inhibition prevented the formation of
distant metastases (30). Moreover, the immunosuppressive
effect of increased prostaglandin production (1) may allow
circulating tumor cells to escape the host antitumor response
Fig. 5. Kaplan-Meier survival estimates by dichotomized COX-2 tumor epithelial staining in irradiated rectal tumors for local recurrence (A), overall survival (B), and
disease free survival (C). Gray lines, low levels of COX-2; black lines, high levels of COX-2 expression. High COX-2 expression is a poor prognostic factor for disease-free
(P = 0.004) and overall survival in irradiated rectal cancer patients (P = 0.006).
Fig. 4. Kaplan-Meier survival estimates by dichotomized COX-2 tumor epithelial
staining in irradiated (RT+) and nonirradiated (RT-) rectal tumors. Distant
recurrence rates estimates by COX-2 tumor epithelial staining in irradiated and
nonirradiated patients. COX-2 expression does not have an effect on distant
recurrences in nonirradiated tumors (gray lines , P = 0.77) but significantly effects
distant recurrences in irradiated tumors (black lines , P = 0.005).
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and metastasize. However, it is not very likely that these events
will take place during the short interval between completion of
radiation and surgery.
It has been established in several animal models and clinical
studies that COX-2 inhibitors synergize with radiotherapy and
can be given safely (28, 31–33). COX-2 inhibitors could prevent
the adverse effects of elevated COX-2 levels and subsequent
increased prostaglandin production that can occur during
radiotherapy. It is tempting to speculate that the addition of
COX-2 inhibitors to preoperative radiotherapy may help to
reduce distant recurrences and improve patient survival.
In the current study, using patients from a trial that evaluated
TME surgery with or without preoperative radiotherapy, COX-2
expression did not have any effect on local recurrence rates or
prognosis in nonirradiated tumors. We have not studied
pretreatment biopsies, but our results regarding nonirradiated
tumors indicate that evaluation of COX-2 expression in
nonirradiated rectal cancer specimens or preradiation biopsies
is not a useful discriminator for response to therapy or
prognosis. The prognostic value of COX-2 expression has
extensively been investigated in retrospective studies with
colorectal cancer specimens (refs. 14, 15; reviewed in ref. 9),
but the independent prognostic value of COX-2 expression
remains unclear. The disagreement on the prognostic value of
COX-2 in colorectal cancer in previous studies might be due to
the apparent lack of prognostic value of COX-2 expression in
nonirradiated rectal cancer as seen in the current study, hereby
confounding the results in studies that compile rectal and colon
patients. The low numbers of COX-2 negative tumors in the
current study (<1%) compared with the 10% to 30% negative
tumors reported in studies evaluating COX-2 expression in
colorectal cancer specimens (34) suggest a biological difference
in tumors originating from the proximal or distal large bowel.
Whether this is due to a larger number of mismatch repair
defective tumors (which show reduced COX-2 expression; refs.
35, 36) in right-sided tumors (37, 38) or other factors is beyond
the scope of the current study. However, the apparent differ-
ences in tumor biology do confound the evaluation of the
clinical relevance of COX-2 expression in the large bowel and
underscore the need for COX-2 assessment in well-defined,
standardized, and uniformly treated patient groups as was done
in the present study.
In conclusion, in the current study we showed that high
levels of COX-2 after radiotherapy are associated with di-
minished apoptosis and high distant recurrence rates. Our data
indicate that evaluation of COX-2 expression after radiotherapy
can be used to identify patients with a poor prognosis. These
results suggest that the addition of COX-2 inhibitors to
preoperative radiotherapy may help to reduce distant recur-
rences and improve patient survival.
Table 2. Results of multivariate COX regression analysis of overall survival among 510 irradiated rectal
cancer patients
Variable HR 95% CI P
Patient age <0.0001
Below median 1
Above median 1.03 1.01-1.05
Tumor-node-metastasis stage <0.0001
I 1
II 1.83 1.22-2.74
III 2.88 1.96-4.22
Circumferential margin <0.0001
Negative 1
Positive 1.94 1.41-2.67
Distance of tumor from the anal verge 0.07
10.1-15 cm 1
5.1-10 cm 1.48 1.03-2.13
V5 cm 1.44 1.01-2.03
COX-2 expression 0.009
Low 1
High 1.46 1.10-1.94
NOTE: A variable was included in the multivariate analysis if the P value in the univariate analysis was <0.10. Patients with missing data were
excluded from the analysis.
COX-2 Expression in Rectal Cancer
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